Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | DRD1 | P21728 | 1/20 | 0.53 |
| ▸ | HTR2B | P41595 | 1/20 | 0.53 |
| ▸ | CCR2 | P41597 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MIF | P14174 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL28255518 | 0.85 | ALDH1A1 (0.40) | SLC6A4ALDH1A1ABCB11NR3C1CYP1A2 | |
| SCHEMBL12104293 | 0.83 | SLC6A4 (0.33) | SLC6A4ALDH1A1ABCB11NR3C1CYP1A2 | |
| SCHEMBL19856414 | 0.83 | CYP3A4 (0.40) | SLC6A4ALDH1A1ABCB11NR3C1CYP1A2 | |
| SCHEMBL28255517 | 0.81 | ALDH1A1 (0.37) | SLC6A4ALDH1A1ABCB11NR3C1CYP1A2 | |
| SCHEMBL5380803 | 0.81 | ALDH1A1 (0.68) | SLC6A4ALDH1A1ABCB11NR3C1CYP1A2 | |
| SCHEMBL15084213 | 0.80 | SLC6A4 (0.36) | SLC6A4ALDH1A1ABCB11NR3C1CYP1A2 | |
| SCHEMBL28483096 | 0.79 | SLC6A4 (0.49) | SLC6A4ALDH1A1ABCB11NR3C1CYP1A2 | |
| SCHEMBL28493334 | 0.78 | ABCB11 (0.47) | SLC6A4ALDH1A1ABCB11NR3C1CYP1A2 | |
| SCHEMBL486820 | 0.77 | MTNR1A (0.36) | SLC6A4ALDH1A1ABCB11NR3C1CYP1A2 | |
| SCHEMBL1997655 | 0.77 | ALDH1A1 (0.75) | SLC6A4ALDH1A1ABCB11NR3C1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113336769-B | Thienopyrimidine ketone acyl sulfonamide derivative as well as preparation method and application thereof | 山东大学 | 2022-06-24 | — | — | CN | claimed |
| CN-113336769-A | Thienopyrimidone acylsulfonamide derivative and preparation method and application thereof | 山东大学 | 2021-09-03 | — | — | CN | claimed |
| CN-106083680-B | A kind of preparation method of 4- cyclopropyl -1- naphthalenylisothiocyanates | 山东川成医药股份有限公司 | 2018-11-02 | — | — | CN | claimed |
| CN-106083680-A | A kind of preparation method of 4 cyclopropyl 1 naphthalenylisothiocyanate | 山东川成医药股份有限公司 | 2016-11-09 | — | — | CN | claimed |
| CN-104710374-A | New compound for gout and preparation method thereof, and application and pharmaceutical preparation of new compound | ANHUI YIXINMING PHARMACEUTICAL TECHNOLOGY CO LTD | 2015-06-17 | — | — | CN | claimed |
| CN-102040546-A | Preparation method of 4-cyclopropyl-1-naphthaline isothiocyanate and intermediate 4-cyclopropyl-1-naphthaldehyde oxime/halide | TAIZHOU CITY HWASUN PHARMACUETICAL AND CHEMICAL CO LTD | 2011-05-04 | — | — | CN | claimed |
| CN-113336769-B | Thienopyrimidine ketone acyl sulfonamide derivative as well as preparation method and application thereof | 山东大学 | 2022-06-24 | — | — | CN | disclosed |
| CN-110878057-B | Method for preparing Raxinader | 江苏宇田医药有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-113979958-A | Preparation method of Raschindde related impurities | 海南鑫开源医药科技有限公司 | 2022-01-28 | — | — | CN | disclosed |
| CN-113336769-A | Thienopyrimidone acylsulfonamide derivative and preparation method and application thereof | 山东大学 | 2021-09-03 | — | — | CN | disclosed |
| CN-111153862-B | Raisinard refining method | 北京鑫开元医药科技有限公司海南分公司 | 2021-07-06 | — | — | CN | disclosed |
| CN-111116500-B | Purification method of Resinard key intermediate | 北京鑫开元医药科技有限公司海南分公司 | 2021-06-08 | — | — | CN | disclosed |
| CN-111763218-B | Thienopyrimidinone thioglycolic acid derivative and preparation method and application thereof | 山东大学 | 2021-05-28 | — | — | CN | disclosed |
| US-20080176850-A1 | S-Triazolyl Alpha-Mercaptoacetanilides as Inhibitors of Hiv Reverse Transcriptase | ARDEA BIOSCIENCES, INC. | 2008-07-24 | — | — | US | disclosed |
| US-20080176850-A1 | S-Triazolyl Alpha-Mercaptoacetanilides as Inhibitors of Hiv Reverse Transcriptase | ARDEA BIOSCIENCES, INC. | 2008-07-24 | — | — | US | disclosed |
| EP-1789039-A2 | S-TRIAZOLYL ALPHA -MERCAPTOACETANILDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | Ardea Biosciences, Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2007050087-A1 | N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES, INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007050087-A1 | N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES, INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20060270725-A1 | N[S(4-aryl-triazol-3-yl)alpha-mercaptoacetyl]-p-amino benzoic acids as HIV reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2006026356-A2 | S-TRIAZOLYL α-MERCAPTOACETANILDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ARDEA BIOSCIENCES, INC. (US) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270725-A1 | N[S(4-aryl-triazol-3-yl)alpha-mercaptoacetyl]-p-amino benzoic acids as HIV reverse transcriptase inhibitors | NQO2, NAT1, QPCT | SLC6A4 399/4885ALDH1A1 903/4885ABCB11 1318/4885 |
| US-20080176850-A1 | S-Triazolyl Alpha-Mercaptoacetanilides as Inhibitors of Hiv Reverse Transcriptase | SPR, POLR2H, QTRT1 | SLC6A4 1394/4885ALDH1A1 1574/4885ABCB11 3108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.